Why TG Therapeutics Stock Was Soaring This Week
Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.TG Therapeutics got the ball rolling before the trading week kicked off, publishing its Q4 and full-year 2024 results Monday morning.These revealed that the commercial-stage biotech earned just under $108.2 million in revenue for the quarter, which was more than double the nearly $44 million in the same period of 2023. On the bottom line, the company flipped to a generally accepted accounting principles (GAAP) net income of $23.3 million ($0.15 per share) from the year-ago deficit of $14.4 million. Continue reading
Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.
TG Therapeutics got the ball rolling before the trading week kicked off, publishing its Q4 and full-year 2024 results Monday morning.
These revealed that the commercial-stage biotech earned just under $108.2 million in revenue for the quarter, which was more than double the nearly $44 million in the same period of 2023. On the bottom line, the company flipped to a generally accepted accounting principles (GAAP) net income of $23.3 million ($0.15 per share) from the year-ago deficit of $14.4 million.
